Taimur Shah, MD, Author at Grand Rounds in Urology

Taimur Shah, MD

Imperial College London

London, UK

Taimur Shah, MBBS, BSc, FRCS, PhD, is a Clinical Associate Professor and Consultant Urologist at Imperial College London in England. Dr. Shah has a sub-specialist interest in prostate cancer diagnostics, imaging, robotic surgery, focal therapy for prostate cancer, and minimally invasive treatments for benign prostatic hyperplasia.

Dr. Shah earned his medical degree from University College London in England, focusing on focal therapy for newly diagnosed prostate cancer and for cancer that recurs after radiotherapy. While there, he was also awarded a First-Class Honours degree in Molecular Medicine. He then completed his urological training in the London Deanery, rotating through the Charing Cross Hospital, the Royal Marsden Hospital, Barnet and Chase Farm Hospitals, and the Whittington Hospital in London. Dr. Shah then completed a uro-oncology fellowship in Robotic Surgery at Guys and St Thomas’ Hospital in London.

Dr. Shah has helped design and deliver multiple clinical trials for primary, metastatic, and radio-recurrent prostate cancer and is currently part of the Imperial Prostate group at Imperial College London. He has been an advocate for collaborative as well as trainee-led research and previously spent five years as Vice Chair of the British Urology Researchers in Surgical Training research collaborative.

Talks by Taimur Shah, MD

Case Discussions II-Complications and Recurrences

Abhinav Sidana, MD, MPH, FACS, Arvin K. George, MD, Phillip Stricker, MBBS, Taimur Shah, MD, Thomas P. Frye, DO and Alice Yu, MD | Aug 2024

Abhinav Sidana, MD, MPH; Arvin K. George, MD; Phillip Stricker, MBBS; Taimur T. Shah, MD; Alice Yu, MD; and Thomas Frye, DO;

Clinical Trials in Focal Therapy – Endpoint, Design, Updates

Taimur Shah, MD | Aug 2024

Taimur Shah, MD, provides an in-depth analysis of clinical trials in focal therapy for prostate cancer, focusing on endpoints, design, and recent updates.

Dr. Shah emphasizes the importance of carefully defined endpoints in clinical trials for focal therapy, including oncologic control measures such as progression-free survival, biochemical recurrence rates, and cancer-specific mortality. Secondary endpoints typically assess functional outcomes, including urinary continence and sexual function, to gauge the impact on patients’ quality of life. These criteria are crucial for determining the effectiveness and safety of focal therapy compared to traditional treatments.

The design of clinical trials in focal therapy is discussed in detail. Dr. Shah highlights the need for robust methodologies, including randomized controlled trials (RCTs) and prospective cohort studies. He discusses the latest data on various focal therapy modalities, including high-intensity focused ultrasound (HIFU), cryoablation, and photodynamic therapy.

The presentation also addresses the challenges and limitations of current clinical trials. These include the need for standardized treatment protocols, variability in imaging and biopsy techniques, and the difficulty of conducting long-term follow-ups. Dr. Shah emphasizes the importance of continued research and collaboration among institutions to overcome these challenges and refine focal therapy approaches.